Kidney Week

This Year's Updates

• New category: Augmented Intelligence, Digital Health, and Data Science - Artificial intelligence (AI), digital health research and interventions, electronic medical records (EMRs) analysis, multi-modal data science, end-to-end system development and usability studies. Clinical trials or observational studies, quality control studies or initiatives, or diversity, equity, and inclusion (DEI) and disparities research or initiatives in these topic areas.
• The Kidney Week 2023 Annual Meeting will take place in-person on November 2-5, 2023, in Philadelphia, PA. Oral abstracts and posters must be presented in-person in Philadelphia.

Eligibility

• All research abstracts, clinical case reports, informational posters, and late-breaking clinical trials must be submitted electronically through the ASN abstract submission site by their respective deadlines for consideration. Please refer to the Important Deadlines below.
• ASN requires abstract Submitters to have an ASN User Login, and ALL abstract authors to have an ASN User Login AND 24 months of FULL disclosures on file with ASN. Authors must submit their own disclosures. (Click here for the ASN Conflict of Interest and Disclosure Policy.) Please allow adequate time to gather this information by May 24, 2023.
  • ASN membership is not required to create a User Login. There is no fee to create a User Login.
  • Click here if the Submitter/author needs to create a User Login.
  • Click here if the Submitter/author has a User Login but forgot his/her password.
  • ALL authors must provide FULL disclosures BEFORE they can be added to an abstract.
  • Authors must submit their OWN disclosures.
• ASN membership is not required to submit, be an author on, or present an abstract.
• The Presenting (First) Author of an accepted oral or poster abstract must register for the Annual Meeting (fees apply).
• Submission of multiple abstracts on a single study may result in the rejection of one or more of the abstracts.
• Abstracts are NOT eligible for consideration if the research will have been presented at another meeting or press conference prior to Kidney Week.
• Abstracts are NOT eligible for consideration if the research has been published or accepted for publication by May 24, 2023.
• Posting of un-refereed manuscripts to a community preprint server by authors will not be considered prior publication, provided that the following conditions are met:
  • During submission, authors must acknowledge preprint server deposition.
  • Versions of a manuscript that have been altered as a result of the peer review process may not be deposited.
  • The preprint version cannot be indexed (e.g., in MEDLINE or PubMed).
  • Upon ASN publication, authors are responsible for updating the archived preprint version with a link to the ASN Abstract Supplement PDF.
    • The preprint server should meet NIH standards for interim research product repositories.
• All research and studies in submitted abstracts must comply with the WMA Declaration of Helsinki, the Declaration of Istanbul on Organ Trafficking and Transplant Tourism, and the NIH Guide for the Care and Use of Laboratory Animals.

Important Deadlines

• Research abstracts and clinical case reports ("abstracts") must be submitted by 2:00 p.m. EDT (Eastern time) on Wednesday, May 24, 2023. Abstracts may be edited until the deadline. Abstracts that are unpaid or have payment issues will not be considered. If the Submitter does not receive a payment confirmation email titled "Abstract Payment Confirmation," please check for it in spam/junk folders, then email kidneyweek@asn-online.org to confirm the abstract's submission status.
• Changes: It is important that the Presenting (First) Author verifies the abstract data BEFORE submission. Carefully review the "View Proof" link at the bottom of Step 6 in the submission; how the abstract appears in the proof is how it will be published.
  • Through May 24, 2023, at 2:00 p.m. EDT, submitted abstracts may be returned to draft, edited, and re-submitted. Between this date/time and May 31, 2023, for submitted abstracts needing minimal changes, the Submitter or Presenting (First) Author can email kidneyweek@asn-online.org with the abstract number in the subject line and the ASN Abstract Change Form attached.
  • After May 31, 2023, no changes will be allowed, including author updates.
  • If accepted for presentation/publication, abstracts will be printed as they were submitted with any changes as of May 31, 2023. ASN has the authority to make standard copyediting changes (e.g., spelling errors, capitalizations, abbreviations).
• Notifications: ASN will email notifications to the Presenting (First) Authors and Submitters of all research abstract, clinical case report, and informational poster submissions by 11:59 p.m. EDT on August 11, 2023. It is the responsibility of the Presenting (First) Author to share the notification with their co-authors. If you are a Presenting Author and have not received your notification by August 12, 2023, please check for it in spam/junk folders, then email kidneyweek@asn-online.org; note the abstract number in the email subject line and the Presenting Author's name in the email body.
  • If the Presenting Author or Submitter's contact information changes after submission, please email kidneyweek@asn-online.org to confirm the new email address. Updating your email address in your ASN profile does not automatically update it in the abstract submission system.
• Withdrawals: The Presenting (First) Author can request abstract withdrawal through June 30, 2023, by emailing kidneyweek@asn-online.org. Please note the abstract number in the email subject line and the Presenting (First) Author's name in the email body. The $75 processing fee is nonrefundable. After June 30, withdrawal requests will be accepted on a case-by-case basis, but the abstract may still appear in meeting publications.
• Informational Posters: The informational poster submission period opens on June 14, 2023, and closes on July 12, 2023, 2:00 p.m. EDT.
• Late-Breaking Clinical Trials: The late-breaking clinical trials submission period opens on July 19, 2023, and closes on September 6, 2023, 2:00 p.m. EDT.

Submission Types

Research Abstracts

• All types of nephrology-related research are eligible for submission and should address scientific questions, detail clinical observations, or contain preliminary original scientific data.
• There is no limit to the number of research abstracts that an individual may submit, but only one abstract per study should be submitted. Submission of multiple abstracts on a single study may result in the rejection of one or more of the abstracts.
• Accepted research abstracts may be assigned for oral presentation, assigned for poster presentation, and/or published in the ASN Abstract Supplement PDF.
• Important! If your research data are available by May 24, 2023, ASN strongly recommends that you submit your abstract during the regular call for abstracts, rather than holding it for the call for late-breaking clinical trials. The regular call for abstracts has more opportunities for oral presentations and posters than the call for late-breaking clinical trials.

Clinical Case Reports

• Case reports must include uniqueness of the case, clinical findings presented, outcomes documented, and "take-away" lessons (teaching points).
• There is a limit of 2 case report submissions per Presenting (First) Author.
• Accepted case reports may be assigned for poster presentation and/or published in the ASN Abstract Supplement PDF (generally not assigned for oral presentation).

Informational Posters

• Informational Poster submissions will be accepted June 14 - July 12, 2023, 2:00 p.m. EDT.
• Submissions must include research services in core facilities at academic or nonprofit institutions as well as ongoing clinical trials open to enrollment. The purpose is to stimulate utilization of research core facilities and enrollment in clinical trials.
• Abstracts describing clinical trial results are NOT eligible for consideration.
• Accepted informational posters will be assigned for poster presentation but will not be published in the ASN Abstract Supplement PDF.

Late-Breaking Clinical Trials

• Late-Breaking Clinical Trial submissions will be accepted July 19 - September 6, 2023, 2:00 p.m. EDT. Guidelines and instructions specific to late-breaking submissions will be posted in June.
• Accepted late-breaking clinical trials may be assigned for oral presentation, assigned for poster presentation, and/or published in the ASN Abstract Supplement PDF.

Submission Details

Click here to view an abstract submission tutorial.

• All research abstracts, clinical case reports, informational posters, and late-breaking clinical trials must be submitted electronically through the ASN abstract submission site during their respective submission deadlines.
• The abstract submission may be completed on the first visit to the submission site or may be saved and completed at a later time. An abstract may be submitted and paid for, then returned to draft, edited, and resubmitted for no additional fee by May 24, 2023, at 2:00 p.m. EDT.
• The $75 processing fee per research abstract, clinical case report, or informational poster submission is nonrefundable. The processing fee must be paid at the time of submission by credit card (American Express, MasterCard, or VISA).
• Upon abstract submission, the Presenting (First) Author and co-authors agree to all copyright transfer terms and the ASN embargo policy.
• Authors: With regard to authorship credit, ASN has adopted the criteria recommended by the International Committee of Medical Journal Editors (ICMJE) in the Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals: "authorship be based on...1. Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; AND 2. Drafting the work or revising it critically for important intellectual content; AND 3. Final approval of the version to be published; AND 4. Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved."
• Access to Data: ASN requires that ALL authors have full access to all study data and statistical analyses of the data. If that is not the case, the abstract may be rejected or retracted.
• ALL authors must have an ASN User Login and provide 24 months of FULL disclosures BEFORE they can be added to an abstract. Authors must submit their own disclosures. (Click here for the ASN Conflict of Interest and Disclosure Policy.) Please see Eligibility above for additional details.
  • Submitter/Submitting Author: This individual serves as the secondary point of contact with ASN regarding the submission. The Submitter is not required to be a contributing author (e.g., administrative assistant or student working with the authors) but must have an ASN User Login with current contact information for submission.
  • Presenting (First) Author: This individual is the first author listed in the submission and has the primary responsibility for communications with ASN. The Presenting Author is responsible for ensuring that ALL co-authors approve the submission, publication, and potential presentation. The Presenting Author is responsible for ensuring that ALL co-authors who participated in the study and meet the criteria for authorship are listed on the abstract when it is submitted to ASN. The Presenting Author will give the oral or poster presentation, if the submission is accepted, and should feel comfortable presenting and answering questions in English. Please note that the submission system recognizes the first author as the Presenting Author; these roles cannot be differentiated in the system or in the Kidney Week program. The Presenting Author must be the first author listed.
  • Co-Authors: The co-authors will be listed in the order provided during submission.
• Character Limit: An abstract submission may contain a maximum of 2,500 characters. The total character count includes characters and spaces in the following fields:
  • Title
  • Body
  • Figure(s)
    • Up to 2 figures can be included in a submission
    • Figure count is determined by image height but will not exceed 560 characters
    • Because image height cannot be calculated manually, we recommend uploading, editing, and replacing figures in the submission until an acceptable quality : character ratio is reached
  • Table
    • Up to 1 table can be included in a submission
    • Table count is 50 characters per row
    • For complex tables and in situations where control over formatting is desired, we recommend uploading the table as a figure
  • Author names (as they appear once added on Step 4 of the submission process)
    • Author institutions do not count towards the total characters
• Submission Fields
  • Research Abstracts:
    • Title
    • Background
    • Methods
    • Results
    • Conclusion
    • Table (optional, up to 1)
    • Images (optional, up to 2)
    • Category and Subcategory
    • Keywords
    • Funding Sources/Commercial Support (if applicable)
    • Preprint Server-Associated Accession #s or DOIs (if applicable)
    • Authors
    • Agreement to Copyright Transfer & Other Terms
  • Clinical Case Reports:
    • Title
    • Introduction
    • Case Description
    • Discussion
    • Table (optional, up to 1)
    • Images (optional, up to 2)
    • Category and Subcategory
    • Keywords
    • Preprint Server-Associated Accession #s or DOIs (if applicable)
    • Authors
    • Agreement to Copyright Transfer & Other Terms
  • Informational Posters:
    • Title
    • Description
    • Table (optional, up to 1)
    • Images (optional, up to 2)
    • Category and Subcategory
    • Keywords
    • Funding Sources (if applicable)
    • Authors

Assignment, Notification, and Presentation

All abstract submissions are peer reviewed, and authors' names and institutions are blinded to reviewers. Accepted abstracts will be assigned to one of the following:

• "High-Impact Clinical Studies" Oral Session(s): One to two sessions for late-breaking clinical trials will be held in-person in Philadelphia, PA; one on Friday, November 4, 10:30 a.m. - 12:30 p.m. EDT, and one on Saturday, November 5, 10:30 a.m. - 12:30 p.m. EDT. These sessions will be recorded for later viewing.
• Oral Abstract Sessions: These sessions will be held in-person in Philadelphia, PA on Thursday, November 2, Friday, November 3, and Saturday, November 4, 4:30-6:00 p.m. EDT. These sessions will be recorded for later viewing.
• Posters: Posters will be presented in-person in Philadelphia, PA on Thursday, November 2, Friday, November 3, and Saturday, November 4, 9:30 a.m. - 2:30 p.m. EDT, in the exhibit hall. If accepted for poster presentation, the Presenting (First) Author or a co-author must be available at the poster board at 10:00 a.m. - 12:00 p.m. EDT for presentation and discussion. Poster presenters are encouraged to submit an ePoster to complement their printed poster. ePosters will be available for viewing online starting Thursday, November 2, 10:00 a.m. EDT.
• Publication Only: Some abstracts will be included in the ASN Abstract Supplement PDF but not presented during Kidney Week. To request removal from the Abstract Supplement, the Presenting (First) Author must check the box during the submission process that states: "Please do not include my abstract in the ASN Abstract Supplement if my abstract is not selected for an oral or poster presentation."

Abstracts accepted for oral presentations, posters, and publication will be included in the ASN Abstract Supplement PDF, which will be posted online on October 13, 2023.

It is the responsibility of the Presenting (First) Author to share the notification with their co-authors. If you are a Presenting Author and have not received your notification by August 12, 2023, please email kidneyweek@asn-online.org and note the abstract number in the email subject line and the Presenting Author's name in the email body.

The Presenting Authors of abstracts accepted for oral or poster presentations must register for the Annual Meeting (fees apply) and travel to Philadelphia, PA to present in-person.

Confidential Advanced Access

All abstracts submitted in connection with Kidney Week are disclosed to ASN's peer review committee, employees, and contractors as necessary. Although ASN and its employees or contractors cannot guarantee the confidentiality of submitted abstracts, every effort will be made to ensure confidentiality of submitted material.